

Recent Research on the Health Benefits of Blueberries and Their Anthocyanins

Wilhelmina Kalt,¹ Aedin Cassidy,² Luke R Howard,³ Robert Krikorian,⁴ April J Stull,⁵ Francois Tremblay,⁶ and Raul Zamora-Ros⁷

¹Agriculture and Agri-Food Canada, Kentville Research and Development Centre, Kentville, Nova Scotia, Canada (retired); ²Department of Nutrition, Norwich Medical School, University of East Anglia, Norwich, United Kingdom; ³Department of Food Science, University of Arkansas, Fayetteville, AR, USA; ⁴Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati Academic Health Center, Cincinnati, OH, USA; ⁵Department of Human Ecology, University of Maryland Eastern Shore, Princess Anne, MD, USA; ⁶Department of Ophthalmology and Visual Sciences and Department of Physiology and Biophysics, Dalhousie University, Halifax, Nova Scotia, Canada; and ⁷Unit of Nutrition and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain

ABSTRACT

Awareness of the human health benefits of blueberries is underpinned by a growing body of positive scientific evidence from human observational and clinical research, plus mechanistic research using animal and in vitro models. Blueberries contain a large number of phytochemicals, including abundant anthocyanin pigments. Of their various phytochemicals, anthocyanins probably make the greatest impact on blueberry health functionality. Epidemiological studies associate regular, moderate intake of blueberries and/or anthocyanins with reduced risk of cardiovascular disease, death, and type 2 diabetes, and with improved weight maintenance and neuroprotection. These findings are supported by biomarker-based evidence from human clinical studies. Among the more important healthful aspects of blueberries are their anti-inflammatory and antioxidant actions and their beneficial effects on vascular and gluoregulatory function. Blueberry phytochemicals may affect gastrointestinal microflora and contribute to host health. These aspects have implications in degenerative diseases and conditions as well as the aging process. More evidence, and particularly human clinical evidence, is needed to better understand the potential for anthocyanin-rich blueberries to benefit public health. However, it is widely agreed that the regular consumption of tasty, ripe blueberries can be unconditionally recommended. *Adv Nutr* 2020;11:224–236.

Keywords: anthocyanin, berries, cardiovascular, cognition, diabetes, obesity, processing, vision

Introduction

Blueberries were first popularized as a “super fruit” due mainly to the high in vitro antioxidant capacity of their abundant polyphenolic compounds. However, direct antioxidant action of polyphenolic compounds in situ appears unlikely due to their poor bioavailability (1). Nonetheless, research regarding foods for health performed during the past 2 decades has revealed a multitude of ways in which blueberries are bioactive and beneficial to health.

An increasing body of evidence suggests that blueberries and anthocyanins reduce biomarkers and risk of diseases that constitute major socioeconomic burdens, including cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and neurological decline. In these observational analyses, anthocyanins often provide benefits over and above other plant food phytochemicals, including other flavonoids (2–6). The intake of even moderate amounts of blueberries (approximately one-third cup) and anthocyanins (<50 mg) daily is associated with disease risk reduction (2–4, 6–9).

In this narrative, research on the role of blueberries in cardiometabolic health, neuroprotection, vision, and food processing is reviewed. Observational evidence is presented along with results from human clinical studies, and from animal and in vitro research. Over half of the nearly 200 papers cited in this review were published in the last decade. Blueberry research is the primary focus of this review; however, anthocyanin literature is also discussed where relevant. Interest continues to grow in the potential human health benefits of blueberries.

The United States Highbush Blueberry Council (USHBC) offered support for this article by providing an honorarium to each author but had no role in the design and conduct of the review.

Author disclosures: AC, LRH, RZ-R, no conflicts of interest. AC acts as an advisor to the USHBC grant committee and has received research support from the USHBC. RK, WK, AJS, and FT have received research funding from the USHBC and have no conflict of interest. The USHBC is an agricultural federal research and promotion board established by the USDA. It was founded by and is funded by its members who are blueberry farmers, processors, and importers. The USHBC does not sell any product and operates with independent oversight from the USDA. Address correspondence to WK (e-mail: Wilhelmina.kalt@icloud.com). Abbreviations used: BW, body weight; CVD, cardiovascular disease; RGC, retinal ganglion cell; RPE, retinal pigmentary epithelium; T2DM, type 2 diabetes mellitus.

TABLE 1 Total anthocyanin concentration of popular fruit consumed in the United States

Fruit	Description	Number of samples	Total anthocyanins (mg/100 g fresh)
Apple ¹	Red peel	6	12
Apple ¹	Yellow peel	2	0
Banana ²		—	0
Blackberry ²		4	245
Blueberry ²	Highbush	7	387
Blueberry ²	Lowbush	1	487
Cantaloupe ²		—	0
Cherry (sweet) ²		4	122
Grape ²	Red peel and flesh	5	27
Grape ²	Purple peel and flesh	1	120
Kiwifruit ²		—	0
Nectarine ³	Yellow peel	5	15
Orange ²	Orange flesh	—	0
Plum ³	Yellow peel	1	0
Plum ³	Red peel	2	20
Plum ³	Black peel	2	116
Raspberry (red) ²		5	92
Strawberry ²		8	21
Watermelon ²		—	0

¹Reference 11.²Reference 10.³Reference 12.

Current Status of Knowledge

Blueberry species and composition

Blueberry species of commercial importance include highbush blueberry (*Vaccinium corymbosum* L.), rabbiteye blueberry (*V. virgatum* Aiton), lowbush blueberry (*V. angustifolium* Aiton), and European bilberry (*V. myrtillus* L.). Blueberries are one of the richest sources of anthocyanins among common fruits (10–12) (Table 1). Anthocyanins are the pigments that confer the red, blue, and purple coloration to ripe berries. During berry ripening, anthocyanin content rises dramatically to provide a visual cue to distinguish between early to fully ripe fruit (13).

Among a selection of 80 highbush and 135 lowbush blueberry phenotypes, 90% of the phenotypes spanned a 1.6-fold range in anthocyanin concentration (14). Among the total 215 blueberry phenotypes, the range between the 10th and 90th percentiles of cyanidin-3-glucoside equivalents/g fresh weight was 0.925 to 2.1 mg (14).

Blueberry polyphenolic compounds

Anthocyanin flavonoids account for up to 60% of the total polyphenolics in ripe blueberries (13). Therefore, anthocyanins probably make the greatest contribution to blueberry health benefits. Blueberry polyphenolic compounds include both flavonoid and nonflavonoid types. Other classes of flavonoids found in blueberries include proanthocyanidins (15, 16) and flavonols (17, 18). Abundant nonflavonoid polyphenolic compounds in blueberries are

the hydroxycinnamic acid esters (especially chlorogenic acid) (16, 17, 19, 20).

Anthocyanin bioavailability

Associating the in vivo metabolites of anthocyanins with health outcomes has been difficult. After ingestion, anthocyanins are converted to a large number of products via chemical events and human and microbial metabolism. Clearance time for anthocyanin metabolites varies widely (21, 22). To illustrate, within 6 h after humans ingested ¹³C-labeled anthocyanin, substantial ¹³C-labeled CO₂ was detected in exhaled breath, which demonstrated rapid and complete anthocyanin catabolism. However, >50% of the ¹³C still remained in the body after 48 h (21). Anthocyanins and their phase 2 metabolites persist in urine long after anthocyanin intake (23), probably due to their transport in bile (24, 25). Also, anthocyanins and their metabolites become localized in body tissues (24, 26–29). Due to the catabolic action of gastrointestinal microflora on anthocyanins and other food polyphenolics, phenolic acid products are very abundant in the large intestine (30).

Cardiovascular Health

Population studies in cardiovascular health, berries, and anthocyanins

The association between a higher anthocyanin intake and reduction in all-cause mortality risk in a meta-analysis of 6 studies was principally due to a decreased cardiovascular mortality risk (31). Similar findings were reported in a meta-analysis of total CVD (RR: 0.89; 95% CI: 0.83–0.96) (32). In 3 cohort studies, a higher anthocyanin intake was associated with an ~25% reduced risk of coronary artery disease, including fatal and nonfatal myocardial infarction (33, 34). Higher intakes of blueberries, strawberries, and total anthocyanins were all associated with a 32% lower rate of myocardial infarction, and this association was independent of established risk factors (2). However, in 2 prospective cohort studies no association was found between anthocyanin intake and stroke risk (34, 35).

Higher anthocyanin intake was associated with an ~8–10% reduction in hypertension risk in 5 cohort studies (3, 36, 37). A higher anthocyanin intake was associated with a 10% lower risk of incident hypertension in a cohort of over 87,000 participants examined over a period of 14 y (3). The greatest risk reduction was observed in women aged ≤60 y (3). One biomarker, vascular stiffness, was measured in a cross-sectional study of 1898 carefully phenotyped twins. In this study, a clinically relevant improvement in vascular modulation, measured using pulse wave velocity, was associated with greater anthocyanin intake (6).

Population studies in CVD, obesity, berries, and weight maintenance

Obesity and overweight are major contributors to CVD risk (38). Even minor weight gain can increase the risk

of hypertension (39) and CVD (40, 41). Reducing BMI by 1–3 kg/m² was associated with a 2–13% lower risk of CVD events (41) and mortality (42). In a comparison of intakes of 16 common fruits, the highest blueberry intake was associated with the least weight gain (−0.64 kg over 4 y) in a prospective study of over 133,000 men and women followed for ≤ 24 y (43). Among 6 classes of flavonoids, a higher anthocyanin intake had the strongest association with less weight gain (−0.1 kg per 10 mg anthocyanins) in a study of 124,000 individuals (44).

Greater anthocyanin intake was associated with 3–9% lower fat mass and less central adiposity in healthy female twins ($n = 2734$) (45) based on body composition assessment using DXA (46). In this study, the twin with the higher blueberry intake had a lower fat mass ratio than the co-twin (45). Results of the twin studies are most interesting because they are independent of genetic and common environmental factors.

Clinical studies in cardiovascular health

In clinical research on blueberries, subjects most often have some CVD risk (e.g., metabolic syndrome markers, T2DM). In a placebo-controlled study of 58 diabetic patients, blueberry intake led to a decline in LDL cholesterol, triglycerides, and adiponectin and an increase in HDL cholesterol (47). Intake of purified anthocyanin for 12 wk by 150 hypercholesterolemic subjects was associated with an increase in HDL cholesterol and a decrease in LDL cholesterol as well as improved endothelial function (brachial flow-mediated dilation) (48). Then, after 24 wk of anthocyanin intake by the same 150 hypercholesterolemic patients, a reduction was documented in inflammatory markers, including serum high-sensitivity C-reactive protein, soluble vascular adhesion molecule-1, and plasma IL-1 β (49).

Arterial stiffness was reduced and both systolic and diastolic blood pressure were decreased by 5–6% after 8 wk of blueberry intake in women with pre- and stage 1 hypertension (50, 51). Similar benefits were observed in middle-aged unmedicated men with CVD risk factors (51). In subjects with metabolic syndrome, vascular endothelial function was improved although blood pressure was unaffected by blueberry intake for 6 wk (52). In a blueberry study examining participants with metabolic syndrome ($n = 115$), after 6 mo of taking either 0, 75, or 150 g, biomarkers of cardiometabolic function were unchanged in the group taking 75 g blueberries daily. However, the group taking 150 g blueberries daily had sustained improvements in vascular function and lipid status. Insulin resistance was not affected by either dose of blueberries (53). Some clinical studies have reported little to no effect of blueberry intake on blood pressure (54, 55). In contrast to these long-term studies, in a 6-h acute study design, blueberry intake was associated with short-term improvements in vascular function measured by flow-mediated dilation in 21 healthy men (56).

Mechanisms of cardiovascular benefit

Blueberries and anthocyanins benefit cardiovascular health via antioxidant and anti-inflammatory effects (49, 57) positive effects on plasma lipid levels, and modulation of glucose metabolism and endothelial function (see reviews, 58, 59). Blueberries protect vasculature in various ways that can be detected by vascular responsiveness, blood pressure, and arterial stiffness (18, 50–52, 60). These benefits may involve NO metabolism (53, 61) and effects on endothelium composition (62) and plasma lipids (47, 48, 63). Most often, cardiovascular research models employ a relevant stress treatment (e.g., diet or disease) or examine a population with existing risk condition(s).

Nonflavonoid catabolites of berry anthocyanins predominate in the large intestine (1) and could interact with the microbiota to elicit anti-inflammatory or other responses that contribute to cardioprotective benefits (64). Blueberry supplementation modified the colonic microflora of rats (65, 66). By use of gene sequencing, 3 new phyla and 22 new genera of micro-organisms were found to be specifically associated with blueberry feeding (66). These gene changes accounted for $\sim 9\%$ of the entire genome and were associated with species in the intestinal mucin layer, as well as better protection from bacterial invasion and greater capacity for xenobiotic metabolism (66). In a study with high-fat-fed rats, blueberry intake moderated the negative effects of the high-fat diet on inflammation and insulin signaling and also led to modification of the gut microbiota (67).

Prediabetes and T2DM

Population studies in T2DM, blueberries, and anthocyanins

Prediabetes and T2DM affect ~ 100 million adults in the United States (68). Both prediabetes and T2DM are characterized by poor response to insulin stimulation (i.e., insulin resistance) leading to inefficient glucose uptake and metabolism in insulin-sensitive tissues (69). Of all the fruits analyzed in 3 prospective studies, blueberries provided the strongest association, with T2DM risk reduction of 26% (RR: 0.74; 95% CI: 0.66–0.83) (70). In the same cohorts, when the intake of habitually consumed flavonoids (flavonols, flavones, flavanones, flavan-3-ols, and anthocyanins) was examined, intake of anthocyanins and particularly blueberries provided a similar degree of risk reduction of 23% with consumption of ≥ 2 servings weekly or ≤ 1 serving monthly. There was no association found between the intake of total flavonoid or other flavonoid groups and reduced T2DM risk (4).

A meta-analysis of data from 3 US cohorts associated T2DM risk reduction with higher intake of anthocyanins (RR: 0.85, 95% CI: 0.80–0.91) and berry fruits (RR: 0.82, 95% CI: 0.76–0.89) (71). A similar association between T2DM risk reduction with greater anthocyanin intake was determined in a Polish cohort (RR: 0.68, 95% CI: 0.48–0.98) (72). In a cross-sectional study in women, higher habitual intake of anthocyanins and flavones was associated with improvements

in insulin resistance, whereas only anthocyanin was associated with a decrease in inflammation and high-sensitivity C-reactive protein (8). Obesity is positively associated with T2DM risk (73). Greater blueberry and anthocyanin intake is associated with less weight gain during aging (43–45) and therefore would support reduced T2DM risk. Notably, not all observational studies identified an association of anthocyanin or berry intake with reduced T2DM risk (74, 75).

Clinical studies in T2DM

In a placebo-controlled study of obese, insulin-resistant adults, insulin sensitivity was greater after 6 wk of blueberry intake (76). Insulin sensitivity was assessed using a hyperinsulinemic-euglycemic clamp, which directly measures whole-body glucose disposal (77).

Anthocyanin extract from bilberry and black currant (80 mg daily) improved insulin sensitivity (HOMA-IR), plasma lipid profiles, and reduced plasma markers of oxidative stress among 58 T2DM patients compared to placebo (47). When glucose-modulation effects were examined in a T2DM population after a single oral dose of either placebo or 0.47 g standardized bilberry extract containing 36% (w/w) anthocyanins, bilberry intake lowered plasma glucose and insulin AUC in the oral glucose tolerance test (78). In a 12-wk trial of 54 overweight young adults, replacing 50 g carbohydrate with 50 g blueberries daily produced favorable reductions in body weight (BW), insulin, cholesterol, and other metabolic factors (63).

Animal and mechanistic studies in T2DM

Rodents with a phenotype and metabolic features of prediabetes and T2DM, plus diet-induced obesity, are often used to investigate mechanisms of action. C57BL/6 mice fed a high-fat (60%) diet for 8 wk had better insulin sensitivity when blueberries were added to the high-fat diet (79). Also, the glucose AUC of the mice fed a high-fat diet plus blueberries was similar to that of mice fed the low-fat diet (79).

In a study where Zucker fatty rats were fed a high-fat (45%) or low-fat (10%) diet, after 12 wk rats receiving a high-fat diet plus 2% blueberries and those fed a low-fat diet had better metabolic markers than mice fed a high-fat diet without blueberries. At that time rats fed a high-fat diet plus blueberries had better measures of fasting insulin levels, insulin resistance (HOMA-IR), and glucose AUC than high-fat–fed controls (80). Blueberry intake reduced markers of metabolic syndrome and adiposity in high-fat–fed, obesity-prone rats (80).

Insulin resistance (HOMA-IR) and glucose tolerance in obese mice were improved after 12–15 wk of diet supplementation with blueberries (81–83). Obese hyperglycemic mice that consumed blueberry powder that was sorbed and concentrated on defatted soybean flour had improved oral glucose tolerance and fasting glucose concentration, compared to controls (83).

Several but not all biomarkers of glucose metabolism were normalized by blueberry intake in obese Zucker rats (84).

In other obese rodent studies, blueberry intake improved glucose tolerance (85) or not (86), and in some studies insulin responses were not improved (65, 84, 85, 87). However, in high-fat–fed mice, inflammatory markers and hypertension that are associated with obesity were mitigated (87).

Berry intake supports the growth of favorable mucin-producing bacteria that can protect of the lining of the gastrointestinal tract, which may mitigate lower intestinal and systemic inflammation and improve metabolic outcomes (88, 89).

Neuroprotection, Cognition, and Blueberries

Population studies in neuroscience, blueberries, and anthocyanins

In a pooled analysis of 2 US cohort studies which examined almost 150,000 people, lower Parkinson disease risk was associated with the highest quintile of anthocyanin (RR: 0.76) and berry (RR: 0.77) intake ($P = 0.02$) (90). In a prospective analysis of 16,000 women in the Nurse's Health Study, greater intake of blueberries and strawberries was associated with slower rates of cognitive decline in older adults, with an estimated delay in decline of about 2.5 y (5).

The risk for Alzheimer disease and other dementias is associated with cardiovascular and metabolic health risk biomarkers, including obesity and insulin resistance in midlife (91–93). Inasmuch as anthocyanins are protective against CVD and T2DM risks, greater anthocyanin intake may be associated with reduced risk of Alzheimer-type dementia in late life.

Clinical studies in neuroscience and blueberries

Cognitive performance in elderly adults improved after 12 wk of daily intake of blueberry (94) or Concord grape (95) juice. Better task switching and reduced interference in memory was found in healthy older adults after 90 d of blueberry supplementation (96). Blueberry powder intake led to modest benefits in memory performance and subjective improvements in everyday function among 39 older adults with cognitive complaints (97). These kinds of improvements reflected better executive ability (97). Interestingly, relatively modest benefits were found in cognitively unimpaired older adults (96, 97) compared with benefits measured in participants with mild cognitive impairment.

After 12 wk of blueberry consumption, greater brain activity was detected using magnetic resonance imaging in healthy older adults during a cognitive challenge. The detection was associated with enhanced perfusion in regions mediating cognitive function (98). Similarly, during a memory test, regional blood oxygen level-dependent activity detected by MRI (99) was enhanced in the subjects taking blueberry, but not in those taking placebo. All subjects in this study had mild cognitive impairment (99).

Cognitive benefits were detected in school-aged children in an acute study design where performance on a list-learning task was improved 2 h after consuming a single dose of blueberry powder but not placebo (100). Improvement in

executive and long-term memory in children was associated with their intake of blueberry powder, with evidence of a dose-response (15 compared with 30 g powder) (101). In a crossover trial with children 7- to 10-y old, a single 30-g dose of blueberry powder produced enhanced executive performance on a timed and graded executive task (102).

Detecting cognitive benefits of blueberries in healthy children could be facilitated by tasks that involve a greater cognitive demand (102). Indeed, advancements in cognitive assessment tools will aid in examining specific populations. In particular, methods are needed to measure blueberry effects in cognitive domains involved in nonpathological aging, as opposed to domains affected by neuropathologies like Alzheimer disease. Statistical techniques such as covariate control and difference scores can help to identify the effects of phytochemicals like anthocyanins amid uncontrolled interindividual variation in factors such as cognitive capability, phase 2 metabolism, and intestinal microflora.

Animal and mechanistic studies on blueberries and the brain

Blueberries improved cognitive and motor performance of aged rats, making them comparable to young animals (103, 104). Similar age-related improvements were observed in old mice (105). Blueberry-related improvements in long-term spatial memory of rodents is widely reported (29, 105–108). Cognitive benefits of blueberries in tasks that engaged working memory and learning are also documented (105, 108, 109).

Blueberry supplementation protected middle-aged mice from deficits in cognitive performance related to a high-fat diet (110). This is interesting in light of the rising incidence of obesity-related metabolic disorders (111) and the association between cardiometabolic markers in middle-aged humans and Alzheimer dementia risk later in life (91–93).

Blueberry supplementation protected vulnerable brain regions, reduced deficits in spatial memory, and mitigated markers of inflammation and oxidative stress in a rat model of accelerated aging due to high-energy particle exposure (112, 113). In a cell culture model of kainic acid-induced inflammation, treatment with blueberry polyphenolic fractions led to improved calcium buffering and reduced hippocampal neuron loss (114). Blueberry supplementation correlated with increases in hippocampal cAMP response element-binding protein phosphorylation and concentrations of brain-derived neurotrophic factor and improved performance in spatial working memory tasks of old animals (115).

Blueberry feeding is reported to upregulate neurogenesis, neuroplasticity, brain-derived neurotrophic factor, and insulin-like growth factor 1 in aged (106) and in young (107) rodents. Blueberry anthocyanidin glycosides and their phase 2 metabolites can cross the blood–brain barrier and are detectable in various brain tissues (24, 27–29, 116, 117).

Blueberries and Anthocyanins in Vision and Eye Health

Visual function, retinal stress, and anthocyanins

During vision, light reaching the eye is wavelength-filtered through the cornea, lens, and vitreous humor and focused onto the neural retina. Then retinal photoreceptors convert light energy into an electrical signal that is transmitted to the brain's visual centers via the axons of the retinal ganglion cells (RGCs).

The retina has the highest respiratory rate of any other mammalian tissue (118, 119) and is a significant source of oxidative stress. The outer segment of the retinal photoreceptor cell is rich in photopigments (opsin and 11-*cis* retinol) imbedded in membranes rich in polyunsaturated fatty acids which are constantly being renewed (120), thereby creating very favorable conditions for oxidative stress (121). Oxidative stress and cell proliferation are exacerbated by pathological responses to irradiation of the retina (122), neovascularization (123), and inflammation (124, 125). Markers of oxidative stress and inflammation increase with normal aging and can trigger a tissue-adaptive response (parainflammation) to restore homeostasis in the retina (126).

Although the retina is protected by an active blood–brain barrier at the retinal pigmentary epithelium (RPE), anthocyanins can be detected in ocular tissues. Anthocyanins were selectively distributed to ocular tissues after oral, intravenous, or intraperitoneal administration in rats and rabbits (26). In pigs fed diets containing 0%, 1%, 2%, or 4% (w/w) blueberries, anthocyanins were detected in the whole eye in a dose-dependent manner (127).

Population studies on anthocyanins and vision

There are currently very few observational studies examining anthocyanin intake in relation to ocular disease risk. A higher total flavonoid intake was associated with a reduced risk of cataracts in a Finnish population of 10,054 subjects (128). In a prospective cohort study of >35,000 women aged ≥ 45 y, there was a significant association between blueberry intake and a reduced risk of incident total and visually significant age-related macular degeneration, but there was no association with incident cataract (H Sesso, Brigham and Women's Hospital, personal communication, 2019). Although macular degeneration is the leading cause of visual impairment during aging in the developed world, there are no studies that examine anthocyanin intake in relation to macular degeneration.

Clinical studies on berry anthocyanins and vision

Compared to animal and in vitro research, there are relatively few clinical studies examining anthocyanin effects on human vision, particularly studies that adequately satisfy design criteria, including randomization, blinding, placebo control, and crossover, as previously described (129, 130). In normotensive glaucoma patients ($n = 30$), visual field defects were stabilized, ocular blood flow was improved, and

plasma endothelin was normalized after 6 mo of daily intake of black currant anthocyanin (50 mg) (131). Similar benefits were observed in a trial in patients medicated for open-angle glaucoma, who received 25 mg anthocyanin daily for 2 y (132). Beneficial effects on intraocular pressure were also observed in a crossover study ($n = 21$) after only 4 wk of 50 mg daily intake (133).

Mirtogenol (bilberry and pine bark extract), corresponding to ~ 30 mg anthocyanin taken daily for 6 mo, provided additive benefit to ocular hypertensive patients (134), who were taking a widely used glaucoma treatment, prostaglandin F2a analog (Latanoprost) (135). The additive effect of Mirtogenol could have been due to normalization of capillary filtration, an antihypertensive effect related to vascular permeability. This effect was also suggested in a study of diabetic retinopathy patients using Tegens, a product similar to Mirtogenol (136). In a study of blueberries, the same protective effect was documented in an *in vitro* model of lipotoxicity-induced vascular endothelial dysfunction where greater NO bioavailability was linked to the blueberry effect (137).

An improvement in contrast sensitivity was associated with the intake of 510 mg bilberry anthocyanins daily in Tagen-F for 12 mo in human subjects with nonproliferative diabetic retinopathy ($n = 88$) (138). In a 1-mo crossover trial of 30 (139) and 60 normal subjects (140), anthocyanin intake was associated with an improved capacity for visual accommodation and a decrease in ocular fatigue of myopic subjects, possibly by improving contrast sensitivity.

Improvements were reported in dark adaptation threshold between highest dose and placebo, and visual accommodation shifts after a single dose ingestion of black currant concentrate at 12.5, 20, or 50 mg/dose (141). In two other recent crossover studies of normal-sighted adults ($n = 60$ and 72) there was no effect of blueberry juice intake on dark adaptation or dark-adapted visual acuity or contrast sensitivity, although a mild improvement in recovery time after retinal photobleaching was found (142). Interestingly, photobleaching recovery effects occurred with daily doses of either 7 or 346 mg blueberry anthocyanins and after both 3 and 12 wk of intake. In studies where low doses of anthocyanins were taken by healthy humans for a short term, there was no improvement in dark adaptation threshold, visual acuity, or contrast sensitivity (143–146), which conflicts with earlier research which reported such benefits (for review, see references 129 and 130).

Blueberry and anthocyanin effects in animal models of vision

In studies using light-induced retinal photoreceptor degeneration, which is a widely used model of human retinal dystrophies (147), neuroprotection by blueberry species was convincingly documented with both long-term (5–35 d) (148, 149) and short-term (2–72 h) (149–153) prophylactic treatments with daily anthocyanin doses between 10 and 500 mg. Retinal inflammation, which is a hallmark of many ocular pathologies, was mitigated in mice fed bilberry extract

(500 mg/kg BW) for 4 d after inflammation was induced by intraperitoneal injection of LPS (154). In the bilberry group, retinal electrophysiology was improved, rhodopsin was preserved, and there was less damage to photoreceptors compared to controls (154). In a similar model of retinal inflammation, mice fed for 5 d with 50–200 mg/d bilberry showed a dose-dependent decrease in neurotoxic NO and malondialdehyde, combined with an increase in neuroprotective antioxidant capacity due to glutathione, vitamin C, superoxide dismutase, and glutathione peroxidase (155).

Other ocular pathologies targeting primarily the RGC have also been investigated. The degeneration of RGC *in vivo* was mitigated with bilberry extract intake [100 mg/(kg · d)] in a mouse model of optic nerve injury. Bilberry extract (1%) mitigated RGC damage *in vitro* during oxidative conditions created with 3-(4-morpholinyl) sydnonimine hydrochloride (156). Bilberry also protected RGC of mice *in vivo* under oxidative conditions created by *N*-methyl-D-aspartic acid injected into the vitreous (20–100 μ g/eye) (156).

Ocular development can be experimentally influenced by berry intake. When myopia was induced in young chicks by interposing a strong minus lens in front of the eye, the impact was less in chicks fed black currant extract (400 mg/kg BW) for 3 d prior to treatment (157). Retinal degeneration and cataract development were slowed with bilberry extract (20 mg/kg BW) in hypertensive OXYS rats that demonstrate senescence-accelerated expression of traits and a short lifespan (158). In neonatal rats where cataracts were induced by subcutaneous injection of sodium selenite, administration of a polyphenol-enriched fraction of bilberry at 40 mg/d was sufficient to prevent cataract formation (159). This effect was probably modulated through the regulation of nuclear factor erythroid 2-related factor 2 and hemoxygenase-1 in the lens (159).

Neonatal mice exposed to a high level of oxygen develop vascular complications similar to the retinopathy of prematurity in humans. Intraocular injection of bilberry extract (300 ng/eye) after neonatal oxygen exposure inhibited the formation of neovascular tufts by possible inhibition of vascular endothelial growth factor A and its downstream-regulated kinases (160).

Blueberries, anthocyanins, and vision physiology examined *in vitro*

The *in vitro* antioxidative capacity of blueberries and their anthocyanins, used either prophylactically or as a treatment, has been demonstrated in vision-relevant models related to oxygen donation (161, 162), quenching of singlet oxygen (163), glutathione synthesis (149, 164), and glutamate insults (165) in both RPE and RGC primary culture cell lines.

The action of anthocyanins as molecular allosteric effectors has been investigated with the receptor protein rhodopsin (166) and with bestrophin, a protein involved in Best vitelliform retinal dystrophy (167). The allosteric actions of anthocyanins and flavonoids to inhibit cataractogenesis *in vitro* has been reported (168–171).

Bilberry anthocyanins improved viability and differentiation of cultured human corneal epithelial cells (172) and wild Chinese blueberry (*V. uliginosum* L.) produced similar benefits in the RPE cell line D407 (173). Blueberry treatment improved the viability and differentiation of human RPE cells during light-induced aging and after multiple replications in vitro (174).

Several studies document a potential role for flavonoids to improve retinal photoreceptor sensitivity in vitro by affecting the rate of rhodopsin regeneration (166, 175–177), or by modulating the inhibition of downstream G proteins involved in the phototransduction cascade (178, 179), or by downregulating retinoid-binding proteins (163). In an in vitro bovine ciliary muscle preparation, anthocyanins interacted with the endothelin-1 pathway to reduce muscle contractility, which relates to accommodative processes for distance vision in myopic eyes (180).

Blueberries, Anthocyanins, and Food Processing

Fresh blueberries are delicate and often processed soon after harvest to preserve them. Individual quick freezing is a widely used means to preserve blueberries, to retain vitamin C, total phenolics, anthocyanins, and antioxidant capacity (181). The percentage loss of blueberry anthocyanins during -18°C storage was 12% after 10 mo of storage (181).

Dried blueberries can be stored at room temperature. Whereas conventional thermal dehydration can cause significant losses to anthocyanins (182), freeze-drying is an excellent means to remove water while preserving blueberry phytochemical quality (183). Freeze-dried blueberry powder loses anthocyanins in a temperature-dependent manner with a half-life of 139, 39, and 12 d when stored at 25, 42, and 60°C , respectively (184).

Radiant zone drying of blueberry extract did not affect anthocyanin or total phenolic content (185). Nonthermal technologies such as high pressure and pulsed electric fields used in conjunction with refrigerated storage helped to retain blueberry vitamin C, total phenolics, and anthocyanins immediately after processing (186).

Blueberries can be processed into shelf-stable products (e.g., canned fruit, juices, and preserves); however, processing can lead to changes in the phytochemical profile. During juice and purée processing, heat, oxygen, and enzymes can degrade blueberry phytochemicals, with greatest losses to vitamin C and anthocyanins. Blueberries are low in ascorbic acid and high in anthocyanins (187), and notably anthocyanins are readily degraded by ascorbic acid (188, 189).

Homogenization of whole blueberries leads to oxidative loss of anthocyanins, proanthocyanidins, and flavonols, due to polyphenol oxidase (190). Enzyme-catalyzed oxidative damage can be mitigated by blanching prior to milling and depectinization (191). Pasteurization to inactivate microorganisms and enzymes typically results in minor ($<10\%$) losses of blueberry polyphenolic compounds, although product flavor can be adversely affected (192). Polyphenolic

compounds are lost when polyphenolic-rich skins and seeds in the press cake are physically removed (193–195).

Shelf-stable blueberry products like jam (196), juice (197), and extracts (198) can lose polyphenolic compounds when stored at ambient temperature whereas refrigeration mitigates losses. Blueberry processing can drastically change fruit composition; therefore, processing methods that optimize extraction and shelf stability of health-beneficial compounds are worthy objectives.

Conclusions

Selected research documenting blueberries as a health-promoting food has been presented. Evidence supporting a role for blueberries and anthocyanins in human health is outlined according to human observational and clinical evidence, followed by mechanistic research using animal and in vitro models. Blueberry treatments generally produce larger effects in experimental models involving stress or disease risk.

The relative amount of evidence presented supporting cardiovascular, glucoregulation, neuroprotection, and vision benefits differs. For example, whereas there is abundant epidemiological evidence for the cardioprotective effects of blueberries and anthocyanins, epidemiological evidence for blueberry or anthocyanin benefits in human vision is lacking. And where there is substantial clinical evidence showing blueberry-related improvements in cognition and brain function, there is relatively little epidemiological evidence on anthocyanins in this area.

The anti-inflammatory, antioxidant, and vasoprotective effects of blueberry components together contribute to well-regulated glucose delivery to insulin-sensitive tissues and good metabolic function. Each of these aspects has implications in multiple areas of healthy aging. Notably, biomarkers of cardiometabolic dysfunction are associated with risk for vascular and Alzheimer-type dementia in late life (92, 93), which may be related to the mitigation of neuroinflammation.

Improvement in anti-inflammatory biomarkers associated with blueberry intake is supported by observational (8), clinical (48), animal (87), and in vitro (114) evidence. Anti-inflammatory and immune benefits of blueberries may involve mucin-associated and other colonic microbiota (67), which constitutes a new domain for berry health research.

Blueberry benefits have been observed in both short-term (see, for example, references 18, 78, and 100) and long-term human interventions (see, for example, references 76 and 94), which suggests multiple modes of action.

In blueberry health research, several important areas remain poorly understood. For example, the dose dependency of clinical effects is mostly unclear (18, 101, 142). The bioactivity of anthocyanin metabolites in vivo, both collectively and individually, is still mostly unknown, as is the importance to health of anthocyanins localized in tissues. Another important question is the relative bioactivity in the colon of phenolic breakdown products of blueberry anthocyanins compared with similar phenolic compounds

from other plant foods in the diet. Notably, these gaps in knowledge do not detract from our ability to tap into blueberry health benefits by increasing public consumption.

This review of research findings will hopefully aid consumers, healthcare providers, and the food and health industry to understand the current state of knowledge on blueberries and health. It can be safely stated that daily moderate intake (50 mg anthocyanins, one-third cup of blueberries) can mitigate the risk of diseases and conditions of major socioeconomic importance in the Western world.

Acknowledgments

RZ-R thanks the “Miguel Servet” program (CP15/00100) from the Institute of Health Carlos III (Spain) and the European Social Fund. The authors’ responsibilities were as follows—WK: edited the manuscript and also co-authored content on blueberries and vision; WK, AC, LRH, RK, AJS, FT, RZ-R: each prepared a draft on their topic; and all authors: reviewed and could revise subsequent versions received from the editor (WK) and read and approved the final manuscript.

References

- Williamson G, Clifford MN. Colonic metabolites of berry polyphenols: the missing link to biological activity? *Br J Nutr* 2010;104:S48–66.
- Cassidy A, Mukamal KJ, Liu L, Franz M, Eliassen AH, Rimm EB. High anthocyanin intake is associated with a reduced risk of myocardial infarction in young and middle-aged women. *Circulation* 2013;127:188–96.
- Cassidy A, O’Reilly EJ, Kay C, Sampson L, Franz M, Forman JP, Curhan G, Rimm EB. Habitual intake of flavonoid subclasses and incident hypertension in adults. *Am J Clin Nutr* 2011;93:338–47.
- Wedick NM, Pan A, Cassidy A, Rimm EB, Sampson L, Rosner B, Willett W, Hu FB, Sun Q, van Dam RM. Dietary flavonoid intakes and risk of type 2 diabetes in US men and women. *Am J Clin Nutr* 2012;95:925–33.
- Devore E, Kang HJ, Breteler MM, Grodstein F. Dietary intakes of berries and flavonoids in relation to cognitive decline. *Ann Neurol* 2012;72:135–43.
- Jennings A, Welch AA, Fairweather-Tait SJ, Kay C, Minihane A-M, Chowienczyk P, Jiang B, Cecelja M, Spector T, Macgregor A, et al. Higher anthocyanin intake is associated with lower arterial stiffness and central blood pressure in women. *Am J Clin Nutr* 2012;96:781–8.
- Cassidy A, Rogers G, Peterson JJ, Dwyer JT, Lin H, Jacques PF. Higher dietary anthocyanin and flavonol intakes are associated with anti-inflammatory effects in a population of US adults. *Am J Clin Nutr* 2015;102:172–81.
- Jennings A, Welch AA, Spector T, Macgregor A, Cassidy A. Intakes of anthocyanins and flavones are associated with biomarkers of insulin resistance and inflammation in women. *J Nutr* 2014;144:202–8.
- McCullough ML, Peterson JJ, Patel R, Jacques PF, Shah R, Dwyer JT. Flavonoid intake and cardiovascular disease mortality in a prospective cohort of US adults. *Am J Clin Nutr* 2012;95:454–64.
- Wu X, Beecher GR, Holden JM, Haytowitz DB, Gebhardt SE, Prior RL. Concentrations of anthocyanins in common foods in the United States and estimation of normal consumption. *J Agric Food Chem* 2006;54:4069–75.
- Tsao R, Yang R, Young JC, Zhu H. Polyphenolic profiles in eight apple cultivars using high-performance liquid chromatography (HPLC). *J Agric Food Chem* 2003;51:6347–53.
- Tomás-Barberán FA, Gil MI, Cremin P, Waterhouse AL, Hess-Pierce B, Kader AA. HPLC–DAD–ESIMS analysis of phenolic compounds in nectarines, peaches, and plums. *J Agric Food Chem* 2001;49:4748–60.
- Kalt W, Lawand C, Ryan DAJ, McDonald JE, Forney CF. Oxygen radical absorbing capacity, anthocyanin and phenolic content of highbush blueberries (*Vaccinium corymbosum* L.) during ripening and storage. *J Am Soc Hortic Sci* 2003;128:917–23.
- Kalt W, Ryan DAJ, Duy JC, Prior RL, Ehlenfeldt MK, Vander Kloet SP. Interspecific variation in anthocyanins, phenolics, and antioxidant capacity among genotypes of highbush and lowbush blueberries (*Vaccinium* section *cyanococcus* spp.). *J Agric Food Chem* 2001;49:4761–7.
- Gu L, Kelm MA, Hammerstone JF, Beecher G, Holden J, Haytowitz D, Gebhardt S, Prior RL. Concentrations of proanthocyanidins in common foods and estimations of normal consumption. *J Nutr* 2004;134:613–7.
- Rodríguez-Mateos A, Cifuentes-Gomez T, Tabatabaee S, Lecras C, Spencer JPE. Procyanidin, anthocyanin, and chlorogenic acid contents of highbush and lowbush blueberries. *J Agric Food Chem* 2012;60:5772–8.
- Cho JM, Howard LR, Prior RL, Clark JR. Flavonoid glycosides and antioxidant capacity of various blackberry, blueberry and red grape genotypes determined by high-performance liquid chromatography/mass spectrometry. *J Sci Food Agric* 2004;84:1771–82.
- Rodríguez-Mateos A, Rendeiro C, Bergillos-Meca T, Tabatabaee S, George TW, Heiss C, Spencer JPE. Intake and time dependence of blueberry flavonoid-induced improvements in vascular function: a randomized, controlled, double-blind, crossover intervention study with mechanistic insights into biological activity. *Am J Clin Nutr* 2013;98(5):1179–91.
- Shukitt-Hale B, Kalt W, Carey AN, Vinqvist-Tymchuk M, McDonald J, Joseph JA. Plum juice, but not dried plum powder, is effective in mitigating cognitive deficits in aged rats. *Nutrition* 2009;25:567–73.
- Kalt W, McDonald JE. Chemical composition of lowbush blueberry cultivars. *J Am Soc Hortic Sci* 1996;121:142–6.
- Czank C, Cassidy A, Zhang Q, Morrison DJ, Preston T, Kroon PA, Botting NP, Kay CD. Human metabolism and elimination of the anthocyanin, cyanidin-3-glucoside: a ¹³C-tracer study. *Am J Clin Nutr* 2013;97:995–1003.
- Kalt W, McDonald JE, Vinqvist-Tymchuk MR, Liu Y, Fillmore SAE. Human anthocyanin bioavailability: effect of intake duration and dosing. *Food Funct* 2017;8:4563–9.
- Kalt W, Liu Y, McDonald JE, Vinqvist-Tymchuk MR, Fillmore SAE. Anthocyanin metabolites are abundant and persistent in human urine. *J Agric Food Chem* 2014;62:3926–34.
- Vanzo A, Vrhovsek U, Tramer F, Mattivi F, Passamonti S. Exceptionally fast uptake and metabolism of cyanidin 3-glucoside by rat kidneys and liver. *J Nat Prod* 2011;74:1049–54.
- Talavéra S, Felgines C, Texier O, Besson C, Lamaison J-L, Rémésy C. Anthocyanins are efficiently absorbed from the stomach in anesthetized rats. *J Nutr* 2003;133:4178–82.
- Matsumoto H, Nakamura Y, Iida H, Ito K, Ohguro H. Comparative assessment of distribution of blackcurrant anthocyanins in rabbit and rat ocular tissues. *Exp Eye Res* 2006;83:348–56.
- Kalt W, Blumberg JB, McDonald JE, Vinqvist-Tymchuk MR, Fillmore SAE, Graf BA, O’leary JM, Milbury PE. Identification of anthocyanins in the liver, eye, and brain of blueberry-fed pigs. *J Agric Food Chem* 2008;56(3):705–12.
- Milbury PE, Kalt W. Xenobiotic metabolism and berry flavonoid transport across the blood brain barrier. *J Agric Food Chem* 2010;58:3950–6.
- Andres-Lacueva C, Shukitt-Hale B, Galli RL, Jauregui O, Lamuela-Raventos RM, Joseph JA. Anthocyanins in aged blueberry-fed rats are found centrally and may enhance memory. *Nutr Neurosci* 2005;8:111–20.
- Kay CD, Kroon PA, Cassidy A. The bioactivity of dietary anthocyanins is likely to be mediated by their degradation products. *Mol Nutr Food Res* 2009;53:S92–101.

31. Grosso G, Micek A, Godos J, Pajak A, Sciacca S, Galvano F, Giovannucci EL. Dietary flavonoid and lignan intake and mortality in prospective cohort studies: systematic review and dose-response meta-analysis. *Am J Epidemiol* 2017;185:1304–16.
32. Wang X, Ouyang YY, Liu J, Zhao G. Flavonoid intake and risk of CVD: a systematic review and meta-analysis of prospective cohort studies. *Br J Nutr* 2014;111:1–11.
33. Goetz ME, Judd SE, Safford MM, Hartman TJ, McClellan WM, Vaccarino V. Dietary flavonoid intake and incident coronary heart disease: the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. *Am J Clin Nutr* 2016;104:1236–44.
34. Cassidy A, Bertola M, Chiuve S, Flint A, Forman J, Rimm EB. Habitual intake of anthocyanins and flavanones and risk of cardiovascular disease in men. *Am J Clin Nutr* 2016;104:587–94.
35. Cassidy A, Rimm EB, O'Reilly EJ, Logroscino G, Kay C, Chiuve SE, Rexrode KM. Dietary flavonoids and risk of stroke in women. *Stroke* 2012;43:946–51.
36. Lajous M, Rossignol E, Fagherazzi G, Perquier F, Scalbert A, Clavel-Chapelon F, Boutron-Ruault M-C. Flavonoid intake and incident hypertension in women. *Am J Clin Nutr* 2016;103:1091–8.
37. Grosso G, Stepaniak U, Micek A, Kozela M, Stefler D, Bobak M, Pajak A. Dietary polyphenol intake and risk of hypertension in the Polish arm of the HAPIEE study. *Eur J Nutr* 2018;57:1535–44.
38. Gregg E, Cheng Y, Cadwell B. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. *JAMA* 2005;293:1868–74.
39. Huang Z, Willett W, Manson J, Rosner B, Stampfer M, Speizer F, Colditz G. Body weight, weight change, and risk for hypertension in women. *Ann Intern Med* 1998;128:81–8.
40. Czernichow S, Mennen L, Bertrais S, Preziosi P, Hercberg S, Oppert J-M. Relationships between changes in weight and changes in cardiovascular risk factors in middle-aged French subjects: effect of dieting. *Int J Obes* 2002;26:1138.
41. Panico S, Palmieri L, Donfrancesco C, Vanuzzo D, Chiodini P, Cesana G, Ferrario M, Mattiello A, Pilotto L, Segna R, et al. Preventive potential of body mass reduction to lower cardiovascular risk: The Italian Progetto CUORE study. *Prev Med (Baltim)* 2008;47:53–60.
42. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, Hollenbeck A, Leitzmann MF. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. *N Engl J Med* 2006;355:763–78.
43. Bertola ML, Mukamal KJ, Cahill LE, Hou T, Ludwig DS, Mozaffarian D, Willett WC, Hu FB, Rimm EB. Changes in intake of fruits and vegetables and weight change in United States men and women followed for up to 24 years: analysis from three prospective cohort studies. *PLoS Med* 2015;12:e1001878.
44. Bertola ML, Rimm EB, Mukamal KJ, Hu FB, Willett WC, Cassidy A. Dietary flavonoid intake and weight maintenance: three prospective cohorts of 124,086 US men and women followed for up to 24 years. *BMJ* 2016;352:i17.
45. Jennings A, MacGregor A, Spector T, Cassidy A. Higher dietary flavonoid intakes are associated with lower objectively measured body composition in women: evidence from discordant monozygotic twins. *Am J Clin Nutr* 2017;105:626–34.
46. Ellis KJ. Human body composition: in vivo methods. *Physiol Rev* 2000;80:649–80.
47. Li D, Zhang Y, Liu Y, Sun R, Xia M. Purified anthocyanin supplementation reduces dyslipidemia, enhances antioxidant capacity, and prevents insulin resistance in diabetic patients. *J Nutr* 2015;145:742–8.
48. Zhu Y, Xia M, Yang Y, Liu F, Li Z, Hao Y, Mi M, Jin T, Ling W. Purified anthocyanin supplementation improves endothelial function via NO-cGMP activation in hypercholesterolemic individuals. *Clin Chem* 2011;57:1524–33.
49. Zhu Y, Ling W, Guo H, Song F, Ye Q, Zou T, Li D, Zhang Y, Li G, Xiao Y, et al. Anti-inflammatory effect of purified dietary anthocyanin in adults with hypercholesterolemia: a randomized controlled trial. *Nutr Metab Cardiovasc Dis* 2013;23:843–9.
50. Johnson SA, Figueroa A, Navaei N, Wong A, Kalfon R, Ormsbee LT, Feresin RG, Elam ML, Hooshmand S, Payton ME, et al. Daily blueberry consumption improves blood pressure and arterial stiffness in postmenopausal women with pre- and stage 1-hypertension: a randomized, double-blind, placebo-controlled clinical trial. *J Acad Nutr Diet* 2015;115:369–77.
51. Erlund I, Koli R, Alftan G, Marniemi J, Puukka P, Mustonen P, Mattila P, Jula A. Favorable effects of berry consumption on platelet function, blood pressure, and HDL cholesterol. *Am J Clin Nutr* 2008;87:323–31.
52. Stull AJ, Cash KC, Champagne CM, Gupta AK, Boston R, Beyl RA, Johnson WD, Cefalu WT. Blueberries improve endothelial function, but not blood pressure, in adults with metabolic syndrome: a randomized, double-blind, placebo-controlled clinical trial. *Nutrients* 2015;7:4107–23.
53. Curtis PJ, van der Velpen V, Berends L, Jennings A, Feelisch M, Umpleby AM, Evans M, Fernandez BO, Meiss MS, Minnion M, et al. Blueberries improve biomarkers of cardiometabolic function in participants with metabolic syndrome—results from a 6-month, double-blind, randomized controlled trial. *Am J Clin Nutr* 2019;108:1535–45.
54. Basu A, Du M, Leyva MJ, Sanchez K, Betts NM, Wu M, Aston CE, Lyons TJ. Blueberries decrease cardiovascular risk factors in obese men and women with metabolic syndrome. *J Nutr* 2010;140:1582–7.
55. McAnulty LS, Collier SR, Landram MJ, Whittaker DS, Isaacs SE, Klemka JM, Cheek SL, Arms JC, McAnulty SR. Six weeks daily ingestion of whole blueberry powder increases natural killer cell counts and reduces arterial stiffness in sedentary males and females. *Nutr Res* 2014;34:577–84.
56. Rodriguez-Mateos A, Rendeiro C, Bergillos-Meca T, Tabatabaee S, George TW, Heiss C, Spencer JP. Intake and time dependence of blueberry flavonoid-induced improvements in vascular function: a randomized, controlled, double-blind, crossover intervention study with mechanistic insights into biological activity. *Am J Clin Nutr* 2013;98:1179–91.
57. Klimis-Zacasa D, Vendrame S, Kristob AS. Wild blueberries attenuate risk factors of the metabolic syndrome. *J Berry Res* 2016;6:225–36.
58. Reis JF, Monteiro VVS, Souza Gomes R, Carmo MM, Costa GV, Ribera PC, Monteiro MC. Action mechanism and cardiovascular effect of anthocyanins: a systematic review of animal and human studies. *J Translational Med* 2016;14(1):315.
59. Pojer E, Mattivi F, Johnson D, Stockley CS. The case for anthocyanin consumption to promote human health: a review. *Compr Rev Food Sci Food Saf* 2013;12:483–508.
60. Kalea AZ, Clark K, Schuschke DA, Klimis-Zacas DJ. Vascular reactivity is affected by dietary consumption of wild blueberries in the Sprague-Dawley rat. *J Med Food* 2009;12(1):21–8.
61. Wu X, Wang TTY, Prior RL, Pehrsson PR. Prevention of atherosclerosis by berries: the case of blueberries. *J Agric Food Chem* 2018;66:9172–88.
62. Kalea AZ, Lamari FN, Theocharis AD, Cordopatis P, Schuschke DA, Karamanos NK, Klimis-Zacas DJ. Wild blueberry (*Vaccinium angustifolium*) consumption affects the composition and structure of glycosaminoglycans in Sprague-Dawley rat aorta. *J Nutr Biochem* 2006;17:109–16.
63. Istek N, Gurbuz O. Investigation of the impact of blueberries on metabolic factors influencing health. *J Funct Foods* 2017;38:298–307.
64. Cassidy A, Minihane A-M. The role of metabolism (and the microbiome) in defining the clinical efficacy of dietary flavonoids. *Am J Clin Nutr* 2017;105:10–22.
65. Vendrame S, Guglielmetti S, Riso P, Arioli S, Klimis-Zacas D, Porrini M. Six-week consumption of a wild blueberry powder drink increases bifidobacteria in the human gut. *J Agric Food Chem* 2011;59:12815–20.
66. Lacombe A, Li RW, Klimis-Zacas D, Kristo AS, Tadepalli S, Krauss E, Young R, Wu VCH. Lowbush wild blueberries have the potential to modify gut microbiota and xenobiotic metabolism in the rat colon. *PLoS One* 2013;8:1–8.

67. Lee S, Keirse KL, Kirkland R, Grunewald ZI, Fischer JG, de La Serre CB. Blueberry supplementation influences the gut microbiota, inflammation, and insulin resistance in high-fat-diet-fed rats. *J Nutr* 2018;148:209–19.
68. Centers for Disease Control and Prevention, National Diabetes Statistics Report. 2017.
69. Haffner SM. The insulin resistance syndrome revisited. *Diabetes Care* 1996;19:275–7.
70. Muraki I, Imamura F, Manson JE, Hu FB, Willett WC, van Dam RM, Sun Q. Fruit consumption and risk of type 2 diabetes: results from three prospective longitudinal cohort studies. *BMJ* 2013;347:f5001.
71. Guo X, Yang B, Tan J, Jiang J, Li D. Associations of dietary intakes of anthocyanins and berry fruits with risk of type 2 diabetes mellitus: a systematic review and meta-analysis of prospective cohort studies. *Eur J Clin Nutr* 2016;70:1360.
72. Grosso G, Stepaniak U, Micek A, Kozela M, Stefler D, Bobak M, Pajak A. Dietary polyphenol intake and risk of type 2 diabetes in the Polish arm of the Health, Alcohol and Psychosocial factors in Eastern Europe (HAPEE) study. *Br J Nutr* 2017;118:60–8.
73. Kahn BB, Flier JS. Obesity and insulin resistance. *J Clin Invest* 2000;106:473–81.
74. Jacques PF, Cassidy A, Rogers G, Peterson JJ, Meigs JB, Dwyer JT. Higher dietary flavonol intake is associated with lower incidence of type 2 diabetes. *J Nutr* 2013;143:1474–80.
75. Nettleton JA, Harnack LJ, Scrafford CG, Mink PJ, Barraj LM, Jacobs JDR. Dietary flavonoids and flavonoid-rich foods are not associated with risk of type 2 diabetes in postmenopausal women. *J Nutr* 2006;136:3039–45.
76. Stull AJ, Cash KC, Johnson WD, Champagne CM, Cefalu WT. Bioactives in blueberries improve insulin sensitivity in obese, insulin-resistant men and women. *J Nutr* 2010;140:1764–8.
77. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. *Am J Physiol Metab* 2008;294:E15–26.
78. Hoggard N, Cruickshank M, Moar K-M, Bestwick C, Holst JJ, Russell W, Horgan G. A single supplement of a standardised bilberry (*Vaccinium myrtillus* L.) extract (36% wet weight anthocyanins) modifies glycaemic response in individuals with type 2 diabetes controlled by diet and lifestyle. *J Nutr Sci* 2013;2:1–9.
79. DeFuria J, Bennett G, Strissel KJ, Perfield JW, 2nd, Milbury PE, Greenberg AS, Obin MS. Dietary blueberry attenuates whole-body insulin resistance in high fat-fed mice by reducing adipocyte death and its inflammatory sequelae. *J Nutr* 2009;139:1510–6.
80. Seymour EM, Tanone II, Urcuyo-Llanes DE, Lewis SK, Kirakosyan A, Kondoleon MG, Kaufman PB, Bolling SF. Blueberry intake alters skeletal muscle and adipose tissue peroxisome proliferator-activated receptor activity and reduces insulin resistance in obese rats. *J Med Food* 2011;14:1511–8.
81. Nair AR, Elks CM, Vila J, Del Piero F, Paulsen DB, Francis J. A blueberry-enriched diet improves renal function and reduces oxidative stress in metabolic syndrome animals: potential mechanism of TLR4-MAPK signaling pathway. *PLoS One* 2014;9:e111976.
82. Wu T, Tang Q, Gao Z, Yu Z, Song H, Zheng X, Chen W. Blueberry and mulberry juice prevent obesity development in C57BL/6 mice. *PLoS One* 2013;8:e77585.
83. Roopchand DE, Kuhn P, Rojo LE, Lila MA, Raskin I. Blueberry polyphenol-enriched soybean flour reduces hyperglycemia, body weight gain and serum cholesterol in mice. *Pharmacol Res* 2013;68:59–67.
84. Vendrame S, Zhao A, Morrow T, Klimis-Zacas D. The effects of wild blueberry consumption on plasma markers and gene expression related to glucose metabolism in the obese Zucker rat. *J Med Food* 2015;18:619–24.
85. Elks CM, Terrebbonne JD, Ingram DK, Stephens JM. Blueberries improve glucose tolerance without altering body composition in obese postmenopausal mice. *Obesity* 2015;23:573–80.
86. Prior RL, Wu X, Gu L, Hager TJ, Hager A, Howard LR. Whole berries versus berry anthocyanins: interactions with dietary fat levels in the C57BL/6 J mouse model of obesity. *J Agric Food Chem* 2008;56:647–53.
87. Mykkanen OT, Huotari A, Herzig K-H, Dunlop TW, Mykkanen H, Kirjavainen PV. Wild blueberries (*Vaccinium myrtillus*) alleviate inflammation and hypertension associated with developing obesity in mice fed with a high-fat diet. *PLoS One* 2014;9:e114790.
88. Roopchand DE, Carmody RN, Kuhn P, Moskal K, Rojas-Silva P, Turnbaugh PJ, Raskin I. Dietary polyphenols promote growth of the gut bacterium *Akkermansia muciniphila* and attenuate high fat diet-induced metabolic syndrome. *Diabetes* 2015;64:2847–58.
89. Anhe FF, Roy D, Pilon G, Dudonne S, Matamoros S, Varin TV, Garofalo C, Moine Q, Desjardins Y, Levy E, et al. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased *Akkermansia* spp. population in the gut microbiota of mice. *Gut* 2015;64:872–83.
90. Gao X, Cassidy A, Schwarzschild MA, Rimm EB, Ascherio A. Habitual intake of dietary flavonoids and risk of Parkinson disease. *Neurology* 2012;78:1138–45.
91. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. *Neurology* 2005;64:277–81.
92. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: Two roads converged. *Arch Neurol* 2009;66:300–5.
93. Razay G, Vreugdenhil A, Wilcock G. The metabolic syndrome and Alzheimer disease. *Arch Neurol* 2007;64:93–6.
94. Krikorian R, Shidler MD, Nash TA, Kalt W, Vinqvist-Tymchuk MR, Shukitt-Hale B, Joseph JA. Blueberry supplementation improves memory in older adults. *J Agric Food Chem* 2010;58:3996–4000.
95. Krikorian R, Nash TA, Shidler MD, Shukitt-Hale B, Joseph JA. Concord grape juice supplementation improves memory function in older adults with mild cognitive impairment. *Br J Nutr* 2010;103:730–4.
96. Miller MG, Hamilton DA, Joseph JA, Shukitt-Hale B. Dietary blueberry improves cognition among older adults in a randomized, double-blind, placebo-controlled trial. *Eur J Nutr* 2018;57:1169–80.
97. McNamara RK, Kalt W, Shidler MD, McDonald J, Summer SS, Stein AL, Stover AN, Krikorian R. Cognitive response to fish oil, blueberry, and combined supplementation in older adults with subjective cognitive impairment. *Neurobiol Aging* 2018;64:147–56.
98. Bowtell JL, Aboob-Bakkar Z, Conway ME, Adlam A-LR, Fulford J. Enhanced task-related brain activation and resting perfusion in healthy older adults after chronic blueberry supplementation. *Appl Physiol Nutr Metab* 2017;42:773–9.
99. Boespflug EL, Eliassen JC, Dudley JA, Shidler MD, Kalt W, Summer SS, Stein AL, Stover AN, Krikorian R. Enhanced neural activation with blueberry supplementation in mild cognitive impairment. *Nutr Neurosci* 2018;21:297–305.
100. Whyte AR, Williams CM. Effects of a single dose of a flavonoid-rich blueberry drink on memory in 8 to 10 y old children. *Nutrition* 2015;31:531–4.
101. Whyte AR, Schafer G, Williams CM. Cognitive effects following acute wild blueberry supplementation in 7- to 10-year-old children. *Eur J Nutr* 2016;55:2151–62.
102. Whyte AR, Schafer G, Williams CM. The effect of cognitive demand on performance of an executive function task following wild blueberry supplementation in 7 to 10 years old children. *Food Funct* 2017;8:4129–38.
103. Joseph JA, Shukitt-Hale B, Denisova NA, Bielinski D, Martin A, McEwen JJ, Bickford PC. Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with

- blueberry, spinach, or strawberry dietary supplementation. *J Neurosci* 1999;19:8114–21.
104. Shukitt-Hale B, Bielinski DF, Lau FC, Willis LM, Carey AN, Joseph JA. The beneficial effects of berries on cognition, motor behaviour and neuronal function in ageing. *Br J Nutr* 2015;114:1542–9.
 105. Beracochea D, Krazem A, Henkous N, Haccard G, Roller M, Fromentin E. Intake of wild blueberry powder improves episodic-like and working memory during normal aging in mice. *Planta Med* 2016;82:1163–8.
 106. Casadesus G, Shukitt-Hale B, Stellwagen HM, Zhu X, Lee H-G, Smith MA, Joseph JA. Modulation of hippocampal plasticity and cognitive behavior by short-term blueberry supplementation in aged rats. *Nutr Neurosci* 2004;7:309–16.
 107. Rendeiro C, Vauzour D, Kean RJ, Butler LT, Rattray M, Spencer JPE, Williams CM. Blueberry supplementation induces spatial memory improvements and region-specific regulation of hippocampal BDNF mRNA expression in young rats. *Psychopharmacology (Berl)* 2012;223:319–30.
 108. Tan L, Yang H, Pang W, Lu H, Hu Y, Ling J, Lu S, Zhang W, Jiang Y. Cyanidin-3-O-galactoside and blueberry extracts supplementation improves spatial memory and regulates hippocampal ERK expression in senescence-accelerated mice. *Biomed Environ Sci* 2014;27:186–96.
 109. Papandreou MA, Dimakopoulou A, Linardaki ZI, Cordopatis P, Klimis-Zacas D, Margaritis M, Lamari FN. Effect of a polyphenol-rich wild blueberry extract on cognitive performance of mice, brain antioxidant markers and acetylcholinesterase activity. *Behav Brain Res* 2009;198:352–8.
 110. Carey AN, Gomes SM, Shukitt-Hale B. Blueberry supplementation improves memory in middle-aged mice fed a high-fat diet. *J Agric Food Chem* 2014;62:3972–8.
 111. Villegas R, Perry IJ, Creagh D, Hinchion R, O'Halloran D. Prevalence of the metabolic syndrome in middle-aged men and women. *Diabetes Care* 2003;26:3198–9.
 112. Poulos SM, Bielinski DF, Carrihill-Knoll KL, Rabin BM, Shukitt-Hale B. Protective effects of blueberry- and strawberry diets on neuronal stress following exposure to 56Fe particles. *Brain Res* 2014;1593:9–18.
 113. Shukitt-Hale B, Carey AN, Jenkins D, Rabin BM, Joseph JA. Beneficial effects of fruit extracts on neuronal function and behavior in a rodent model of accelerated aging. *Neurobiol Aging* 2007;28:1187–94.
 114. Brewer GJ, Torricelli JR, Lindsey AL, Kunz EZ, Neuman A, Fisher DR, Joseph JA. Age-related toxicity of amyloid-beta associated with increased pERK and pCREB in primary hippocampal neurons: reversal by blueberry extract. *J Nutr Biochem* 2010;21:991–8.
 115. Williams CM, El Mohsen MA, Vauzour D, Rendeiro C, Butler LT, Ellis JA, Whiteman M, Spencer JPE. Blueberry-induced changes in spatial working memory correlate with changes in hippocampal CREB phosphorylation and brain-derived neurotrophic factor (BDNF) levels. *Free Radic Biol Med* 2008;45:295–305.
 116. El Mohsen MA, Marks J, Kuhnle G, Moore K, Debnam E, Srail SK, Rice-Evans C, Spencer JPE. Absorption, tissue distribution and excretion of pelargonidin and its metabolites following oral administration to rats. *Br J Nutr* 2006;95:51.
 117. Passamonti S, Vrhovsek U, Vanzo A, Mattivi F. Fast access of some grape pigments to the brain. *J Agric Food Chem* 2005;53:7029–34.
 118. Arden GB, Sidman RL, Arap W, Schlingemann RO. Spare the rod and spoil the eye. *Br J Ophthalmol* 2005;89:764–9.
 119. De Gooyer TE, Stevenson KA, Humphries P, Simpson DAC, Curtis TM, Gardiner TA, Stitt AW. Rod photoreceptor loss in Rho^{-/-} Mice reduces retinal hypoxia and hypoxia-regulated gene expression. *Investig Ophthalmol Vis Sci* 2006;47:5553–60.
 120. Njie-Mbye YF, Chitnis M, Opere C, Ohia S. Lipid peroxidation: pathophysiological and pharmacological implications in the eye. *Front Physiol* 2013;4:366.
 121. Beatty S, Koh H-H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. *Surv Ophthalmol* 2000;45:115–34.
 122. Oliva MS, Taylor HA. Ultraviolet radiation and the eye. *Int Ophthalmol Clin* 2005;45:1–17.
 123. Tanaka J, Nakamura S, Tsuruma K, Shimazawa M, Shimoda H, Hara H. Purple rice (*Oryza sativa* L.) extract and its constituents inhibit VEGF-induced angiogenesis. *Phyther Res* 2012;26:214–22.
 124. Viringipurampeer IA, Bashar AE, Gregory-Evans CY, Moritz OL, Gregory-Evans K. Targeting inflammation in emerging therapies for genetic retinal disease. *Int J Inflamm* 2013;2013:581751.
 125. Whitcup SM, Nussenblatt RB, Lightman SL, Hollander DA. Inflammation in retinal disease. *Int J Inflamm* 2013; doi: <http://dx.doi.org/10.1155/2013/724648>.
 126. Xu H, Chen M, Forrester JV. Para-inflammation in the aging retina. *Prog Retin Eye Res* 2009;28:348–68.
 127. Kalt W, Hanneken A, Milbury P, Tremblay F. Recent research on polyphenolics in vision and eye health. *J Agric Food Chem* 2010;58:4001–7.
 128. Knekt P, Kumpulainen J, Järvinen R, Rissanen H, Heliövaara M, Reunanen A, Hakulinen T, Aromaa A. Flavonoid intake and risk of chronic diseases. *Am J Clin Nutr* 2002;76:560–8.
 129. Canter PH, Ernst E. Anthocyanosides of *Vaccinium myrtillus* (Bilberry) for night vision—a systematic review of placebo-controlled trials. *Surv Ophthalmol* 2004;49:38–50.
 130. Tremblay F, Kalt W. Anthocyanins in visual performance and ocular diseases. In: Wallace TC, Guisti MM, editors. *Anthocyanins in health and disease*. Boca Raton (FL): CRC Press; 2014. p. 245–77.
 131. Ohguro I, Ohguro H, Nakazawa M. Effects of anthocyanins in black currant on retinal blood flow circulation of patients with normal tension glaucoma. A pilot study. *Hirosaki Med J* 2007;59:23–32.
 132. Ohguro H, Ohguro I, Katai M, Tanaka S. Two-year randomized, placebo-controlled study of black currant anthocyanins on visual field in glaucoma. *Ophthalmologica* 2012;228:26–35.
 133. Ohguro H, Ohguro I, Yagi S. Effects of Black currant anthocyanins on intraocular pressure in healthy volunteers and patients with glaucoma. *J Ocul Pharmacol Ther* 2013;29:61–7.
 134. Steigerwalt RDJ, Belcaro G, Morazzoni P, Bombardelli E, Burki C, Schönla F. Mirtogenol® potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects. *Clin Ophthalmol* 2010;4:471–6.
 135. Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH. Mechanism of action of Bimatoprost, Latanoprost, and Travoprost in healthy subjects: a crossover study. *Ophthalmology* 2008;115:790–5 e4.
 136. Perossini M, Guidi G, Chiellini S, Siravo D. Studio clinico sull'impeigo degli antocianosidi del mirtillo (Tegens) nel trattamento delle microangiopati retiniche di topo diabetico ed ipertensivo. *Ann Ottal Clin Ocul* 1987;113:1173–90.
 137. Bharat D, Cavalcanti RRM, Petersen C, Begaye N, Cutler BR, Costa MMA, Ramos RKL, Ferreira MR, Li Y, Bharath LP, et al. Blueberry metabolites attenuate lipotoxicity-induced endothelial dysfunction. *Mol Nutr Food Res* 2018;62; doi:<http://doi.org/10.1002/mnfr.20170061>.
 138. Kim ES, Yu SY, Kwon SJ, Kwon OW, Kim SY, Kim TW, Ahn JK, Oum BS, Lew YJ, Lee JE, et al. Clinical evaluation of patients with nonproliferative diabetic retinopathy following medication of anthocyanoside: multicenter study. *J Korean Ophthalmol Soc* 2008;49:1629–33.
 139. Kamiya K, Kobashi H, Fujiwara K, Ando W, Shimizu K. Effect of fermented bilberry extracts on visual outcomes in eyes with myopia: a prospective, randomized, placebo-controlled study. *J Ocul Pharmacol Ther* 2013;29:356–9.
 140. Lee J, Lee HK, Kim CY, Hong YJ, Choe CM, You TW, Seong GJ. Purified high-dose anthocyanoside oligomer administration improves nocturnal vision and clinical symptoms in myopia subjects. *Br J Nutr* 2005;93:895–9.

141. Nakaishi H, Matsumoto H, Tominaga S, Hirayama M. Effects of black currant anthocyanoside intake on dark adaptation and VDT work-induced transient refractive alteration in healthy humans. *Altern Med Rev* 2000;5:553–62.
142. Kalt W, McDonald JE, Fillmore SAE, Tremblay F. Blueberry effects on dark vision and recovery after photobleaching: placebo-controlled crossover studies. *J Agric Food Chem* 2014;62:11180–9.
143. Mayser HM, Wilhelm H. Effects of anthocyanosides on contrast vision. *Investig Ophthalmol Vis Sci* 2001;42(Suppl):63.
144. Muth ER, Laurent JM, Jasper P. The effect of bilberry nutritional supplementation on night visual acuity and contrast sensitivity. *Altern Med Rev* 2000;5:164–73.
145. Zadok D, Levy Y, Glovinsky Y. The effect of anthocyanosides in a multiple oral dose on night vision. *Eye* 1999;13:734–6.
146. Levy Y, Glovinsky Y. The effect of anthocyanosides on night vision. *Eye* 1998;12:967.
147. Organisciak DT, Vaughan DK. Retinal light damage: mechanisms and protection. *Prog Retin Eye Res* 2010;29:113–34.
148. Kubota S, Kurihara T, Ebinuma M, Kubota M, Yuki K, Sasaki M, Noda K, Ozawa Y, Oike Y, Ishida S, et al. Resveratrol prevents light-induced retinal degeneration via suppressing activator protein-1 activation. *Am J Pathol* 2010;177:1725–31.
149. Wang Y, Zhang D, Liu Y, Wang D, Liu J, Ji B. The protective effects of berry-derived anthocyanins against visible light-induced damage in human retinal pigment epithelial cells. *J Sci Food Agric* 2015;95:936–44.
150. Liu Y, Song X, Han Y, Zhou F, Zhang D, Ji B, Hu J, Lv Y, Cai S, Wei Y, et al. Identification of anthocyanin components of wild Chinese blueberries and amelioration of light-induced retinal damage in pigmented rabbit using whole berries. *J Agric Food Chem* 2011;59:356–63.
151. Tremblay F, Waterhouse J, Nason J, Kalt W. Prophylactic neuroprotection by blueberry-enriched diet in a rat model of light-induced retinopathy. *J Nutr Biochem* 2013;24:647–55.
152. Stepanyan RRV, Topchyan H, Topchan HV. Processing drug dosage forms from Caucasian bilberry and their influence on the eye retina. *New Armen Med J* 2007;1:65–74.
153. Osada H, Okamoto T, Kawashima H, Toda E, Miyake S, Nagai N, Kobayashi S, Tsubota K, Ozawa Y. Neuroprotective effect of bilberry extract in a murine model of photo-stressed retina. *PLoS One* 2017;12:1–17.
154. Miyake S, Takahashi N, Sasaki M, Kobayashi S, Tsubota K, Ozawa Y. Vision preservation during retinal inflammation by anthocyanin-rich bilberry extract: cellular and molecular mechanism. *Lab Invest* 2011;92:102.
155. Yao N, Lan F, He R-R, Kurihara H. Protective effects of bilberry (*Vaccinium myrtillus* L.) extract against endotoxin-induced uveitis in mice. *J Agric Food Chem* 2010;58:4731–6.
156. Matsunaga N, Imai S, Inokuchi Y, Shimazawa M, Yokota S, Araki Y, Hara H. Bilberry and its main constituents have neuroprotective effects against retinal neuronal damage in vitro and in vivo. *Mol Nutr Food Res* 2009;53:869–77.
157. Iida H, Nakamura Y, Matsumoto H, Takeuchi Y, Harano S, Ishihara M, Katsumi O. Effect of black-currant extract on negative lens-induced ocular growth in chicks. *Ophthalmic Res* 2010;44:242–50.
158. Fursova AZ, Gesarevich OG, Gonchar AM, Trofimova NA, Kolosova NG. Dietary supplementation with bilberry extract prevents macular degeneration and cataracts in senescence-accelerated OXYS rats. *Adv Gerontol* 2005;16:76–79.
159. Choi J-I, Kim J, Choung S-Y. Polyphenol-enriched fraction of *Vaccinium uliginosum* L. protects selenite-induced cataract formation in the lens of Sprague-Dawley rat pups. *Mol Vis* 2019;25:118–28.
160. Matsunaga N, Chikaraishi Y, Shimazawa M, Yokota S, Hara H. *Vaccinium myrtillus* (bilberry) extracts reduce angiogenesis in vitro and in vivo. *Evidence-Based Complement Altern Med* 2010;7:47–56.
161. Tanaka J, Nakanishi T, Shimoda H, Nakamura S, Tsuruma K, Shimazawa M, Matsuda H, Yoshikawa M, Hara H. Purple rice extract and its constituents suppress endoplasmic reticulum stress-induced retinal damage in vitro and in vivo. *Life Sci* 2013;92:17–25.
162. Hanneken A, Lin F-F, Johnson J, Maher P. Flavonoids protect human retinal pigment epithelial cells from oxidative-stress-induced death. *Invest Ophthalmol Vis Sci* 2006;47:3164–77.
163. Jang YP, Zhou J, Nakanishi K, Sparrow JR. Anthocyanins protect against A2E photooxidation and membrane permeabilization in retinal pigment epithelial cells. *Photochem Photobiol* 2007;81:529–36.
164. Milbury PE, Graf B, Curran-Celentano JM, Blumberg JB. Bilberry (*Vaccinium myrtillus*) anthocyanins modulate heme oxygenase-1 and glutathione S-transferase-pi expression in ARPE-19 cells. *Invest Ophthalmol Vis Sci* 2007;48:2343.
165. Ishige K, Schubert D, Sagara Y. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. *Free Radic Biol Med* 2001;30:433–46.
166. Yanamala N, Gardner E, Riciutti A, Klein-Seetharaman J. The cytoplasmic rhodopsin-protein interface: potential for drug discovery. *Curr Drug Targets* 2012;13:3–14.
167. Priya SSL, Devi PR, Eganathan P, Topno NS. Structure prediction of Bestrophin for the induced - fit docking of anthocyanins. *Bioinformation* 2012;8:742–8.
168. Varma SD, Mizuno A, Kinoshita JH. Diabetic cataracts and flavonoids. *Science* 1977;195:205–6.
169. Morimitsu Y, Kubota K, Tashiro T, Hashizume E, Kamiya T, Osawa T. Inhibitory effect of anthocyanins and colored rice on diabetic cataract formation in the rat lenses. *Int Congr Ser* 2002;1245:503–8.
170. Stefek M. Natural flavonoids as potential multifunctional agents in prevention of diabetic cataract. *Interdiscip Toxicol* 2011;4:69–77.
171. Li J, Ruzhi Deng, Hua X, Zhang L, Lu F, Coursey TG, Pflugfelder SC, Li D-Q. Blueberry component pterostilbene protects corneal epithelial cells from inflammation via anti-oxidative pathway. *Sci Rep* 2016;6:1–10.
172. Song J, Li Y, Ge J, Duan Y, Sze SCW, Tong Y, Shaw P-C, Ng T-B, Tsui KC, Zhuo Y, et al. Protective effect of bilberry (*Vaccinium myrtillus* L.) extracts on cultured human corneal limbal epithelial cells (HCLEC). *Phyther Res* 2010;24:520–4.
173. Sun M, Lu X, Hao L. Blueberry anthocyanin promotes the growth of human retinal pigment epithelial cells. *Adv J Food Sci Technol* 2007;12:8–14.
174. Liu Y, Song X, Zhang D, Zhou F, Wang D, Wei Y, Gao F, Xie L, Jia G, Wu W. Blueberry anthocyanins: protection against ageing and light-induced damage in retinal pigment epithelial cells. *Br J Nutr* 2012;108:16–27.
175. Matsumoto H, Nakamura Y, Tachibanaki S, Kawamura S, Hirayama M. Stimulatory effect of cyanidin 3-glycosides on the regeneration of rhodopsin. *J Agric Food Chem* 2003;51:3560–3.
176. Tirupula KC, Balem F, Yanamala N, Klein-Seetharaman J. pH-dependent interaction of rhodopsin with cyanidin-3-glucoside. 2. Functional aspects. *Photochem Photobiol* 2009;85:463–70.
177. Wahid F, Jung H, Khan T, Hwang K, Park JS, Chang S-C, Khan MA, Kim YY. Effects of *Rubus coreanus* extract on visual processes in bullfrog's eye. *J Ethnopharmacol* 2011;138:333–9.
178. Ruckstuhl M, Beretz A, Anton R, Landry Y. Flavonoids are selective cyclic GMP phosphodiesterase inhibitors. *Biochem Pharmacol* 1979;28:535–8.
179. Virmaux N, Bizet JC, Nullans G, Ehret S, Mandel P. Modulation of rod cyclic GMP-phosphodiesterase activity by anthocyanidin derivatives. *Biochem Soc Trans* 1990;18:686–7.
180. Matsumoto H, Kamm KE, Stull JT, Azuma H. Delphinidin-3-rutinoside relaxes the bovine ciliary smooth muscle through activation of ETB receptor and NO/cGMP pathway. *Exp Eye Res* 2005;80:313–22.
181. Poiana MA, Moigradean D, Raba D, Aida LM, Popa M. The effect of long-term frozen storage on the nutraceutical compounds, antioxidant properties and color indices of different kinds of berries. *J Food Agric Environ* 2010;8:54–8.
182. Reque PM, Steckert EV, Santos FT, Danelli D, Jablonski A, Flóres SH, Rech R, O Rios A, DeJong EV. Heat processing of blueberries and

- its effect on their physicochemical and bioactive properties. *J Food Process Eng* 2015;39:564–72.
183. Sablani SS, Andrews PK, Davies NM, Walters T, Saez H, Bastarrachea L. Effects of air and freeze drying on phytochemical content of conventional and organic berries. *Dry Technol* 2011;29:205–16.
 184. Fracassetti D, Del Bo C, Simonetti P, Gardana C, Klimis-Zacas D. Effect of time and storage temperature on anthocyanin decay and antioxidant activity in wild blueberry (*Vaccinium angustifolium*) powder. *J Agric Food Chem* 2013;61:2999–3005.
 185. Chakraborty M, Savarese M, Harbertson E, Harbertson J, Ringer KL. Effect of the novel radiant zone drying method on anthocyanins and phenolics of three blueberry liquids. *J Agric Food Chem* 2010;58:324–30.
 186. Barba FJ, Jäger H, Meneses N, Esteve MJ, Frígola A, Knorr D. Evaluation of quality changes of blueberry juice during refrigerated storage after high-pressure and pulsed electric fields processing. *Innov Food Sci Emerg Technol* 2012;14:18–24.
 187. Bhagwat S, Haytowitz DB, Holden JM. USDA database for the flavonoid content of selected foods. Release 3.3. USDA Agricultural Research Service. 2018.
 188. Poeschl L, Langston MS, Lee J, Wrolstad RE. Color degradation in an ascorbic acid-anthocyanin-flavanol model system. *J Food Sci* 1981;46:1218–36.
 189. Stebbins NB, Howard LR, Prior RL, Brownmiller C, Liyanage R, Lay J, Yang X, Qian S. Ascorbic acid-catalyzed degradation of cyanidin-3-O- β -glucoside: Proposed mechanism and identification of a novel hydroxylated product. *Adv Berry Res* 2016;6:175–87.
 190. Kader F, Roverl B, Girardin M, Metche M. Mechanism of browning in fresh highbush blueberry fruit (*Vaccinium corymbosum* L.). Role of blueberry polyphenol oxidase, chlorogenic acid and anthocyanins. *J Sci Food Agric* 1999;74:31–4.
 191. Lee J, Durst RW, Wrolstad RE. Impact of juice processing on blueberry anthocyanins and polyphenolics: Comparison of two pretreatments. *J Food Sci* 2002;67:1660–7.
 192. Howard LR, Prior RL, Liyanage R, Lay JO. Processing and storage effect on berry polyphenols: challenges and implications for bioactive properties. *J Agric Food Chem* 2012;60:6678–93.
 193. Skrede G, Wrolstad RE, Durst RW. Changes in anthocyanins and polyphenolics during juice processing of highbush blueberries (*Vaccinium corymbosum* L.). *J Food Sci* 2000;65:357–64.
 194. Brownmiller C, Howard LR, Prior RL. Processing and storage effects on monomeric anthocyanins, percent polymeric color, and antioxidant capacity of processed blueberry products. *J Food Sci* 2008;73:H72–9.
 195. Brownmiller C, Howard LR, Prior RL. Processing and storage effects on procyanidin composition and concentration of processed blueberry products. *J Agric Food Chem* 2009;57:1896–902.
 196. Howard LR, Castrodale C, Brownmiller C, Mauromoustakos A. Jam processing and storage effects on blueberry polyphenolics and antioxidant capacity. *J Agric Food Chem* 2010;58:4022–9.
 197. Reque PM, Steffens RS, Jablonski A, Flóres SH, Rios AdO, de Jong EV. Cold storage of blueberry (*Vaccinium* spp.) fruits and juice: Anthocyanin stability and antioxidant activity. *J Food Compos Anal* 2014;33:1111–6.
 198. Srivastava A, Akoh CC, Yi W, Fischer J, Krewer G. Effect of storage conditions on the biological activity of phenolic compounds of blueberry extract packed in glass bottles. *J Agric Food Chem* 2007;55:2705–13.